REG - Hikma Pharmaceutical - Holding(s) in Company <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

19/10/2015 11:10

RNS Number : 6781C
Hikma Pharmaceuticals Plc
19 October 2015
Notification of major interests in shares
LONDON, 19 October 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
1
Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached
Hikma Pharmaceuticals PLC
2
Reason for the notification


An acquisition or disposal of voting rights
Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached
No

An event changing the breakdown of voting rights
No

Other (please specify): Compliance with the Transparency Directive
No
3
Full name of the person subject to the notification obligation
FMR LLC
4
Full name of shareholders 
See Section 9
5
Date of the Transaction (and date on which the threshold crossed is reached differently)
15th October 2015
6
Date on which the issuer notified
16th October 2015
7
Threshold that is crossed
5%
8
Notified details
See A, B & C below



A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)
Situation previous to the triggering transaction
Resulting situation after the triggering transaction
Number of shares
Number of voting rights
Number of shares
Number of voting rights
% of voting rights
Direct
Indirect
Direct
Indirect
Direct 
Indirect
Ordinary Shares (0.10 GBP)
GB00B0LCW083
10,012,619
10,012,619

9,940,020

9,940,020

4.98%
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights that may be acquired if the instrument if exercised/converted
% of voting rights
-
-
-
-
-
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument
Exercise Price
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights instrument refers to
% of voting rights
Nominal 
Delta
-
-
-
-
-
-
-
Total A+B+C
Number of Voting rights
% of voting rights
9,940,020
4.98
9
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

Custodian
Day to Day IM
Total
BANK OF NEW YORK BRUSSELS (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
8,485
BANK OF NEW YORK MELLON
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
126,481
BROWN BROTHERS HARRIMAN AND CO
FMRC-FMR CO., INC
62,684

FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED
45,683

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
65,599

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
701,393
CIBC MELLON TRUST (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
13,333
CITIBANK NA, HONG KONG BR (S)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
16,382
JP MORGAN, BOURNEMOUTH (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
9,809

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
147,035
JPMORGAN CHASE BANK
FMRC-FMR CO., INC
3,738,352

FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED
151,087

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
44,698

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
66,040
MELLON BANK NA (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
318,448
NATIONAL ASTL BK MELBOURNE (S)
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
57,922
NATIONAL BANK TRUST (C)
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
14,829
NOMURA TRUST AND BANKING (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
670
NORTHERN TRUST CO (C)
FMRC-FMR CO., INC
188,816

FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED
2,598,333

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
42,554

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
303,271
STATE STREET BANK AND TR CO
FMRC-FMR CO., INC
225,374

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
554,286

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
438,456
Grand Total

9,940,020
Proxy Voting
10
Name of the proxy holder
FMR LLC
11
Number of voting rights proxy holder will cease to hold
72,599
12
Date on which proxy holder will cease to hold voting rights
15th October 2015
13
Additional Information

14
Contact name:
Peter Speirs, Company Secretary
15
Contact telephone number:
020 7399 2772
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUKRRRVWARAAA